WARFARIN SODIUM | A040301 | TARO PHARMACEUTICAL INDUSTRIES LTD
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Foley & Lardner, LLP FDA-2020-P-1878 · 4 docket documents Foley & Lardner LLP filed this citizen petition on behalf of an unnamed client under Section 505(j) of the Federal Food, Drug and Cosmetic Act requesting that the FDA designate Warfarin Sodium Tablets USP 10 mg held by Taro Pharmaceutical Industries Ltd. (ANDA No. 040301) as a suitable additional Re | Other | 2020-09-18 | Withdrawn | Foley & Lardner, LLP |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1091
per ea
Lowest NADAC/Unit
$0.0878
per ea
Brand NDCs
0
Generic NDCs
27
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 51672403501WARFARIN SODIUM 10 MG TABLET | $0.1091 | EA | Generic | — | 2026-10-21 |
| 51672403503WARFARIN SODIUM 10 MG TABLET | $0.1091 | EA | Generic | — | 2026-10-21 |
| 51672402701WARFARIN SODIUM 1 MG TABLET | $0.1024 | EA | Generic | — | 2026-10-21 |
| 51672402707WARFARIN SODIUM 1 MG TABLET | $0.1024 | EA | Generic | — | 2026-10-21 |
| 51672402703WARFARIN SODIUM 1 MG TABLET | $0.1024 | EA | Generic | — | 2026-10-21 |
| 51672403007WARFARIN SODIUM 3 MG TABLET | $0.1008 | EA | Generic | — | 2026-10-21 |
Showing 6 of 27 NDCs.
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.